December 16, 2004 |
Johnson & Johnson, the world's biggest maker of medical devices, said late Wednesday that it agreed to buy defibrillator maker Guidant Corp. for $25.4 billion to gain electrical devices for treating heart disease. In the deal, which had been rumored since last week, New Brunswick, N.J.-based J&J would pay $76 for each share of Indianapolis-based Guidant, 40% of it in cash and the balance in stock, J&J said in a statement. The price for Guidant shares is 10.5% more than on Dec.
May 19, 2004 |
Johnson & Johnson, one of the world's largest healthcare product makers, bought closely held Egea Biosciences Inc. Terms weren't disclosed. San Diego-based Egea, which has about 39 employees, will join Johnson & Johnson's Centocor unit. Egea's technologies will help Centocor -- which introduced one of the earliest antibody medicines, ReoPro -- develop other protein-based biotechnology medicines. Shares of New Brunswick, N.J.-based Johnson & Johnson fell 7 cents to $54.63 on the NYSE.
April 16, 1998 |
Johnson & Johnson said Amgen Inc. will pay it $205 million to compensate for Amgen sales of an anemia drug for uses reserved to Johnson & Johnson in a licensing agreement. The arbitration ends an eight-year dispute stemming from a 1985 agreement that limits Amgen's U.S. sales of its Epogen drug to use for kidney dialysis patients. However, the arbitration order also requires Johnson & Johnson to pay Amgen's legal costs, totaling as much as $100 million.
March 28, 2001 |
Johnson & Johnson, in its biggest deal ever, agreed Tuesday to buy Mountain View, Calif.-based Alza Corp. for about $10.2 billion in stock in a move to strengthen its drug pipeline and allow it to deliver medicines in better ways. The deal, which was expected following reports Monday, will give the New Brunswick, N.J., company several promising new drugs, including Ditropan XL for treating overactive bladder and Concerta, a treatment for attention deficit disorder.
October 16, 2002 |
Johnson & Johnson's third-quarter profit jumped 19%, helped by demand for medical devices and the arthritis medication Remicade. Net income at the world's fourth-biggest drug maker rose to $1.8 billion, or 60 cents a share, from $1.5 billion, or 49 cents, in the year-earlier period. Sales at the New Brunswick, N.J.-based company climbed 13% to $9.1 billion. Johnson & Johnson shares rose $1.73 cents to $59.56 on the NYSE.
July 16, 2003 |
Johnson & Johnson, the world's largest maker of medical devices, said second-quarter earnings dropped 27% on costs for acquisitions and a decline in revenue from its biggest drug, Procrit for anemia. The company also said it was struggling to meet orders for the Cypher heart stent, a drug-coated mesh tube that keeps blood flowing through arteries. Net income fell to $1.21 billion, or 40 cents a share, from $1.65 billion, or 54 cents, a year earlier, the New Brunswick, N.J.-based company said.